What Is the PCAC and Why Does This Vote Matter?
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that evaluates whether specific bulk drug substances should be added to the Section 503A Bulk Drug Substances List โ the federal list that authorizes licensed compounding pharmacies to prepare substances against individual patient prescriptions.
Inclusion on the 503A list is the legal prerequisite for a compounding pharmacy to dispense these peptides to patients. Without it, pharmacies cannot legally compound them regardless of a physician's prescription. The July 23โ24 vote is therefore the single most important regulatory event for peptide access in 2026 โ and arguably the most significant in the category's history.
Key facts researchers and the public should understand about this vote:
- The PCAC vote is advisory, not binding. The committee makes a recommendation; the FDA issues a final rule typically 6โ18 months later.
- A "yes" vote doesn't mean immediate pharmacy access. It starts a rulemaking process. Realistic timeline to licensed pharmacy availability: late 2026 to Q1 2027 at the earliest, if the FDA agrees with a positive recommendation.
- A "no" vote doesn't ban research compounds. Research peptide vendors like Evo Peptides sell compounds for laboratory research use only โ a category distinct from compounding pharmacy dispensing. Research compound sales are governed by different regulations than pharmacy compounding.
- All seven compounds were already removed from Category 2 (the "may not be compounded" designation) on April 23, 2026. The July vote is about creating a new legal compounding channel โ not about re-banning anything.
How We Got Here: The Full Regulatory Timeline
FDA Places 19 Peptides in Category 2
FDA's interim 503A policy adds BPC-157, TB-500, and 17 other compounds to Category 2 โ effectively prohibiting licensed compounding pharmacies from preparing them. Research compound vendors are unaffected; gray market access continues.
HHS Announces Review of 14 Peptides
Under HHS Secretary Robert F. Kennedy Jr., the department announces formal review of 14 Category 2 peptides. RFK Jr. publicly supports expanded compounding access. FDA career scientists begin preparing briefing documents.
Federal Register Notice Confirms July 23โ24 Meeting
FDA publishes official notice of PCAC meeting for 7 of the 14 peptides. Docket FDA-2025-N-6895 opens for public comments. Five more peptides scheduled for a second meeting before February 2027.
All 12 Peptides Removed from Category 2
FDA removes BPC-157, TB-500, and 10 other compounds from Category 2, clearing the path for formal PCAC review. Removal from Category 2 does not automatically authorize compounding โ it only enables the review process.
AP Investigation + FDA Staff Briefing Documents
Associated Press reports that at least 3 PCAC panel members have financial ties to the peptide industry. Same day, FDA career scientists release briefing documents recommending against all seven peptides โ citing insufficient clinical evidence. Creates significant political tension ahead of the vote.
Public Comment Window Closes
Final day for public comments to be considered by the PCAC at the July 23โ24 hearing.
PCAC Convenes โ Vote Underway
Two-day hearing at FDA White Oak Campus in Silver Spring, MD. Day 1: BPC-157, TB-500, KPV, MOTS-c. Day 2: Semax, Epitalon, DSIP. Committee hears presentations, public testimony, deliberates, and votes compound by compound. Results published above as confirmed.
FDA Final Rule (if positive recommendation)
If PCAC recommends inclusion and FDA agrees, formal rulemaking adds the compound to the 503A bulks list. Licensed compounding pharmacies then gain legal authority to prepare it with valid prescriptions.
Second PCAC Meeting โ 5 More Peptides
A second meeting will review the remaining 5 peptides from the February 2026 announcement, including injectable GHK-Cu. Tesamorelin and other compounds are in this second cohort.
Compound-by-Compound Breakdown
Each of the seven peptides has a distinct evidence profile and FDA review history. Here's what FDA career scientists said about each in their June 30 briefing documents โ and what a positive vs negative vote means.
BPC-157 (Day 1, July 23)
FDA reviewed BPC-157 primarily for ulcerative colitis applications. The agency's stated concerns in prior Category 2 placement were immunogenicity risk by certain administration routes and complexity in API characterization. FDA career scientists' June 30 briefing recommended against inclusion, citing no completed human RCT data. Political pressure from the RFK Jr. camp favors a positive recommendation. The panel conflict-of-interest controversy (AP, June 29) adds unpredictability.
Evidence base: Hundreds of preclinical studies (primarily Sikiric lab, Zagreb). One Phase 1/2 IBD program (LP17). No published completed RCTs.
What a yes vote means: Rulemaking begins. Licensed 503A pharmacies could compound BPC-157 against prescriptions in ~6โ18 months. Research compound access is unaffected.
What a no vote means: Compounding pharmacy pathway remains closed for now. Research compound access is unaffected. May be re-nominated for future review.
TB-500 (Day 1, July 23)
FDA reviewed TB-500 (Thymosin Beta-4 fragment) for wound healing. The evidence challenge: TB-500 is a fragment of Tฮฒ4, not the full protein, and the full-protein phase 2 dry eye trial didn't hit endpoints. FDA staff briefing recommended against. Zero completed human RCTs for TB-500 specifically.
KPV (Day 1, July 23)
KPV is an alpha-MSH tripeptide (Lys-Pro-Val) studied for ulcerative colitis via anti-inflammatory and melanocortin receptor mechanisms. Included in Evo Peptides' KLOW 80mg blend. Of the seven compounds, KPV has some of the more targeted evidence for a specific indication (UC) which may give it better odds at PCAC.
MOTS-c (Day 1, July 23)
Mitochondria-derived peptide studied for obesity and metabolic regulation. Novel mechanism โ activates AMPK pathway. Limited clinical data relative to the GLP compound class, but growing interest from longevity research community.
Semax (Day 2, July 24)
ACTH analogue studied for opioid withdrawal, neuroprotection, and BDNF/NGF upregulation. RFK Jr. has publicly named Semax as a compound of personal interest. FDA reviewing for opioid dependence indication โ politically relevant given administration priorities. Sold on Evo Peptides; see Semax research guide.
Epitalon (Day 2, July 24)
Tetrapeptide studied for telomerase activation and anti-aging applications. Longevity community interest is high. Primary research base is Russian โ may face scrutiny on data quality standards by FDA reviewers.
DSIP / Emideltide (Day 2, July 24)
Delta sleep-inducing peptide studied for insomnia. Older research profile; relatively less market demand than BPC-157 or Semax.
What Each Possible Outcome Means for Researchers
โ Yes Vote (Recommend Inclusion)
PCAC recommends the compound for the 503A bulks list. FDA begins rulemaking. Timeline to licensed pharmacy availability: 6โ18 months. Research compound sales continue unchanged in the interim.
โ No Vote (Recommend Exclusion)
PCAC does not recommend inclusion. Compounding pharmacy pathway remains closed for now. Research compound vendors are unaffected. Nominators may re-submit with additional clinical data at a future cycle.
โธ Deferred
Committee requests additional information before voting. Common outcome when evidence is mixed. Essentially means a later review cycle โ often 6โ12 months out.
๐ Conditional
Recommendation with conditions โ specific routes of administration, dosage limits, or patient population restrictions. Increasingly common outcome for the category.
The Tension: FDA Career Staff vs Political Pressure
This vote is unusual because it sits at the intersection of science and politics in a way that creates genuine unpredictability about the outcome.
FDA career scientists released briefing documents on June 30 recommending against all seven compounds. Their consistent position: insufficient human clinical trial data, immunogenicity concerns for certain routes, and API characterization complexity. This is the agency's scientific assessment.
HHS Secretary RFK Jr. has publicly advocated for expanded peptide access, specifically naming BPC-157 and Semax. His influence over the political environment surrounding this committee is significant, and the AP's June 29 investigation found at least three PCAC members with financial ties to the peptide industry โ two of whom actively sell peptides to patients.
The result is a meeting where the committee's scientific assessment and its political environment point in opposite directions. Outcomes that would have been near-certain "no" votes under prior FDA leadership are now genuinely uncertain. The realistic expectation from analysts tracking this is a mixed outcome โ one or two positive votes (KPV and potentially Semax given the opioid crisis priority) with others deferred or rejected.
The February 2027 Meeting: 5 More Peptides
A second PCAC meeting is scheduled before the end of February 2027. The five additional peptides from the February 2026 announcement include injectable GHK-Cu โ which directly affects the Evo Peptides catalog. Tesamorelin is also expected in this cohort.
This page will be updated with the confirmed compound list for the second meeting as that information becomes available.
FAQ
Evo Peptides ships all compounds same-day
Regardless of the PCAC outcome, BPC-157, TB-500, Semax, KPV (KLOW), and all catalog compounds remain available for research purchase. COA-verified, same-day shipping from Wisconsin.
Shop All Compounds Full FDA Status Guide โ